Table 1.
| A Baseline Characteristics of HTx Candidates Under- going Liver Biopsy | |||
|---|---|---|---|
| Listed (n = 52) |
Not listed (n = 16) |
p-value | |
| Age (years) | 57.3 ± 11.2 | 53.9 ± 13.6 | 0.32 |
| Gender (n, % male) | 43 (82.7%) | 11 (68.8%) | 0.29 |
| Race (n, %) | 0.70 | ||
| White | 30 (57.7%) | 10 (62.5%) | |
| African American | 11 (21.2%) | 2 (12.5%) | |
| Hispanic | 5 (9.6%) | 3 (18.8%) | |
| Other | 6 (11.5%) | 1 (6.2%) | |
| Etiology of heart failure (n, %) |
1.0 | ||
| Dilated cardiomyopathy |
12 (23.1%) | 3 (18.8%) | |
| Ischemic | 15 (28.9%) | 5 (31.3%) | |
| Other | 25 (48.1%) | 8 (50.0%) | |
| Medication at evaluation (n, %) |
|||
| Amiodarone | 11 (21.2%) | 2 (12.5%) | 0.72 |
| Anti-platelets | 19 (36.5%) | 2 (12.5%) | 0.12 |
| β-Blockers | 34 (65.4%) | 12 (75.0%) | 0.55 |
| Coumadin | 17 (32.7%) | 9 (56.3%) | 0.09 |
| Diuretics | 48 (92.3%) | 11 (68.8%) | 0.03 |
| Inotropes | 34 (65.4%) | 9 (56.3%) | 0.51 |
| Laboratory data | |||
| Alkaline phosphatase |
113.6 ± 69.1 | 107.9 ± 40.0 | 0.76 |
| ALT (U/liter) | 29.2 ± 23.1 | 37.2 ± 44.6 | 0.50 |
| AST (U/liter) | 30.6 ± 23.5 | 37.2 ± 48.9 | 0.46 |
| Albumin (mg/dl) | 3.6 ± 0.7 | 3.5 ± 0.7 | 0.44 |
| Na (mEq/liter) | 134.8 ± 3.9 | 133.2 ± 4.8 | 0.18 |
| Creatinine (mg/dl) | 1.59 ± 1.14 | 2.24 ± 1.72 | 0.17 |
| Total bilirubin (mg/dl) |
1.97 ± 2.03 | 4.46 ± 9.83 | 0.35 |
| modMELD | 8.72 ± 2.55 | 10.64 ± 3.43 | 0.02 |
| MELD-XI | 17.16 ± 7.72 | 20.21 ± 12.48 | 0.37 |
| HepBsAg/HepBcAb/ HCVAb |
21 (41.2%) | 5 (31.3%) | 0.57 |
| B Fibrosis, Liver and Central Cardiac Hemodynamics and Cardiac Imaging of HTx Candidates Undergoing Liver Biopsy | |||
|---|---|---|---|
| Listed (n = 52) |
Not listed (n = 16) |
p-value | |
| Fibrosis on liver biopsy | |||
| (0–4) | |||
| 0–2 | 43 (78.8%) | 9 (31.3%) | 0.03 |
| > 2–4 | 9 (21.2%) | 7 (68.8%) | |
| Liver hemodynamics | |||
| Liver wedge pressure (mm Hg) |
21.7 ± 7.0 | 22.2 ± 7.1 | 0.82 |
| Liver free (mm Hg) | 15.5 ± 7.0 | 14.7 ± 6.7 | 0.74 |
| Trans-liver gradient (mm Hg) |
9.3 ± 5.0 | 7.2 ± 3.1 | 0.11 |
| Echocardiogram | |||
| LA (mm) | 51.9 ± 10.9 | 46.1 ± 13.1 | 0.13 |
| LVEDD (mm) | 64.3 ± 11.4 | 62.4 ± 15.2 | 0.61 |
| LVEF (%) | 21.9 ± 10.9 | 18.9 ± 6.9 | 0.32 |
| Severe RV dysfunction (n, %) |
20 (39.22%) | 3 (18.8%) | 0.13 |
| Severe TR (n, %) | 10 (19.2%) | 4 (26.7%) | 0.50 |
| Cardiac hemodynamics | |||
| RA (mm Hg) | 12.8 ± 6.7 | 18.1 ± 6.4 | 0.01 |
| Mean PAP (mm Hg) | 31.9 ± 10.9 | 30.0 ± 7.6 | 0.53 |
| PCWP (mm Hg) | 21.8 ± 8.0 | 22.8 ± 6.5 | 0.67 |
| PVR (Wood units) | 3.23 ± 2.09 | 2.33 ± 1.11 | 0.044 |
| TPG (mPAP–PCWP) (mm Hg) |
9.38 ± 4.95 | 7.20 ± 3.05 | 0.11 |
| RA/PCWP | 0.58 ± 0.28 | 0.85 ± 0.34 | 0.004 |
| PA SatO2 (%) | 56.0 ± 10.7 | 49.9 ± 11.5 | 0.07 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; HCV, hepatitis C virus; HepBcAb, hepatitis B core antibody; HepBsAg, hepatitis B surface antigen; HTx, heart transplantation; MELD-XI, Model of End-stage Liver Dysfunction eXcluding International normalized ratio; modMELD, modified Model of End-stage Liver Dysfunction.
HTx, heart transplantation; LA, left atrium; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; mPAP, mean pulmonary artery pressure; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RA, right atrium; RV, right ventricle; SatO2, oxygen saturation; TPG, transpulmonary gradient; TR, tricuspid regurgitation.